End-of-day quote
INDONESIA S.E.
06:00:00 2024-04-18 pm EDT
5-day change
1st Jan Change
1,400
IDR
-1.06%
-5.41%
-13.04%
Sales 2024 *
32,263B
2B
Sales 2025 *
35,129B
2.18B
Capitalization
65,452B
4.06B
Net income 2024 *
3,439B
213M
Net income 2025 *
3,572B
221M
EV / Sales 2024 *
1.92
x
Net cash position
2024
*
3,567B
221M
Net cash position
2025
*
5,545B
344M
EV / Sales 2025 *
1.71
x P/E ratio 2024 *
19.3
x
P/E ratio 2025 *
18.4
x
Employees
13,108
Yield 2024 *
2.22%
Yield 2025 *
2.4%
Free-Float
40.45%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 01
CI
Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy
Feb. 20
MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-30
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-06
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-27
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-28
CI
Nomura Adjusts Kalbe Farma’s Price Target to IDR2,500 From IDR2,250, Keeps at Buy
23-01-30
MT
Progen Co. Ltd. announced that it has received IDR 155.72 billion in funding from PT Kalbe Farma Tbk.
23-01-01
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-30
CI
PT Kalbe Farma Tbk. completed the acquisition of a 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S.
22-10-25
CI
Nomura Adjusts Kalbe Farma's Price Target to 2,250 Rupiahs From 1,905 Rupiahs, Keeps at Buy
22-09-22
MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2022
22-07-28
CI
PT Kalbe Farma Tbk. entered into agreement to acquire 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S.
22-07-24
CI
PT Kalbe Farma Tbk.'s Equity Buyback announced on February 10, 2022, has expired.
22-05-07
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-28
CI
More news
Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy
Feb. 20
MT
Nomura Adjusts Kalbe Farma’s Price Target to IDR2,500 From IDR2,250, Keeps at Buy
23-01-30
MT
Nomura Adjusts Kalbe Farma's Price Target to 2,250 Rupiahs From 1,905 Rupiahs, Keeps at Buy
22-09-22
MT
Nomura Adjusts Kalbe Farma's Price Target to 1,905 Indonesian Rupiahs From1,550 Indonesian Rupiahs, Keeps at Buy
22-01-11
MT
PT KALBE FARMA TBK : Nomura Adjusts Kalbe Farma's Price Target to 1,550 Indonesian Rupiahs From 1,900 Indonesian Rupiahs, Keeps at Buy
21-08-12
MT
More recommendations
1 day -2.75%
1 week -4.39%
Current month -4.07%
3 months -10.44%
6 months -21.61%
Current year -12.11%
More quotes
Managers
Title Age Since
Chief Executive Officer
59
96-12-31
Director of Finance/CFO
-
17-01-31
Chairman
61
97-02-28
Members of the board
Title Age Since
Director/Board Member
59
99-12-31
Director/Board Member
51
07-12-31
Chairman
61
97-02-28
More insiders
Date
Price
Change
Volume
24-04-18
1,400
-1.06%
21 853 800
24-04-18
1,415
-2.75%
25,353,800
24-04-17
1,455
+0.34%
24,631,000
End-of-day quote
INDONESIA S.E., April 17, 2024
More quotes
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
More about the company
Last Close Price
1,415
IDR
Average target price
1,777
IDR
Spread / Average Target
+25.56%
Consensus
1st Jan change
Capi.
-12.11% 4.04B +27.97% 672B +24.04% 550B -7.02% 351B +14.85% 317B +6.25% 292B +2.13% 211B -0.41% 203B -10.06% 194B -11.81% 144B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1